Core Viewpoint - China Mobile has announced the candidates for its centralized procurement project for special optical cables for 2026-2027, with Tongding Interconnection winning the highest bid share of 18.85% at a pre-tax bid price of 238 million yuan [1] Group 1: Procurement Details - The total procurement volume for the special optical cables is approximately 79,400 kilometers, equivalent to 3.131 million core kilometers [1] - The procurement includes five major categories of products: ordinary optical cables, flat optical cables, blown micro cables, optical-electrical composite cables, and self-supporting optical cables, along with various sub-products such as waterline cables, rodent-proof cables, and flame-retardant buried cables [1] Group 2: Company Performance - Tongding Interconnection has been recognized for its product stability, price competitiveness, and large-scale delivery capability, leading to its top bid share among eight candidates [1] - The company has established three production bases in Jiangsu, Anhui, and Sichuan, creating a full industry chain layout that covers everything from preform rods to optical fibers, optical cables, communication cables, power cables, and communication equipment [1] - This vertical integration from raw materials to end products provides a solid foundation for the efficient fulfillment of procurement orders [1]

香港特别行政区政府财经事务及库务局副局长陈浩濂在致辞时表示："香港作为全球最大离岸人民币枢 纽，去年各项业务取得丰硕成果。展望未来，我们将继续通过提升离岸人民币的流动性、优化离岸人民 币的金融基建、丰富人民币投资和风险管理产品三大举措，充分发挥香港独特的角色和功能。" 华夏基金副董事长、总经理李一梅在致辞时表示："人民币国际化正经历着由'贸易结算驱动'向'投资与 储备驱动'的范式跃迁。目前，离岸人民币存款规模已破万亿，点心债异军突起，全球各类机构纷纷来 港发行。在此背景下，人民币资产正日益从全球投资者的'可选项'转变为'必选项'。华夏基金的战略， 正是通过提前储备人民币投资产品将这一趋势落在实处。我们的使命是填补投资产品空白，不断完善人 民币计价的权益、固收及衍生品全链条产品线，通过我们丰富的主动投资管理能力，为全球投资者创造 真正的、具备黏性的Alpha和人民币资产配置工具。" 在圆桌讨论环节，香港证监会中介机构部执行董事叶志衡博士、香港金融管理局助理总裁许怀志、香港 交易所董事总经理兼固定收益及货币产品发展主管范文超，以及华夏基金(香港)产品及战略部主管何 蕊，就离岸人民币生态系统的建设和发展进行了深入探 ...

中证报中证网讯（王佳飞 熊永红）日前，中机寰宇（山东）车辆认证检测有限公司经国家市场监督管 理总局批准，筹建国家新能源机动车质量检验检测中心（山东）（以下简称"中心"）。中心致力于服务 山东乃至华东地区，辐射全国，充分发挥高端检验检测服务的提供者、行业排头兵和技术高地作用，为 新能源机动车产业高质量发展提供重要支撑。 中心落户于山东省德州市。山东省作为全国重要的机动车及零部件生产制造基地，产业基础扎实、发展 势头强劲。中心坚持"四个面向"战略导向，聚焦国家重大工程高原、高寒等极端环境需求，填补超大、 超重、超常服役新能源机动车工况验证与试验能力空白；紧扣产业升级要求，着力破解智能化、绿色 化、轻量化领域标准与检测瓶颈，化解智能发展与质量安全结构性矛盾；立足夯实技术基础现实需要， 系统解决检测装备、核心技术、标准数据等方面"测不了、测不全、测不准"突出问题，全力赋能产业高 质量发展。 中心规划建设多个核心实验室，构建覆盖全场景、全链条的极限验证与科研攻关能力：电磁兼容实验室 具备大空间、高承重优势，采用转毂与高承重分区设置模式，可满足60t超大型机动车的测试需求；节 能排放实验室功率覆盖范围广（19kW～400 ...

展望2026年第一季度，公司预计销售收入在6.5亿美元至6.6亿美元之间，预计毛利率在13%至15%之 间。华虹半导体董事会主席兼总裁白鹏博士表示，公司将通过创新和快速代际迭代，持续高度聚焦于打 造世界级特色工艺技术平台，并深化与国内外战略客户的合作。公司有信心在全球半导体产业变局中把 握增长机遇，力争达到股东的长期期许。(王珞) 产能建设方面，2025年度，公司继续推进扩大产能的战略规划，无锡第二条12英寸生产线(FAB9)一阶 段产能建设超预期完成，上海12英寸制造基地(FAB5)的收购事项有序推进。 通过优化产品组合与降本增效，公司各特色工艺平台均表现强劲，尤其是独立式闪存和电源管理平台， 有力支撑了公司业绩增长与利润率上升。 2月12日晚间，华虹半导体发布了2025年第四季度未经审核的财务业绩。报告显示，公司第四季度销售 收入再创历史新高，达6.599亿美元，同比增长22.4%，环比增长3.9%；当季折合8英寸晶圆付运量达 144.8万片，同比增长19.4%；全年实现销售收入24.021亿美元，同比增长19.9%；第四季度毛利率 13.0%，同比上升1.6个百分点，全年毛利率达到11.8%。 在AI驱 ...

Core Viewpoint - Chengyi Pharmaceutical (603811) announced that four of its products have been selected for the national centralized procurement program, with a procurement period extending to December 31, 2028, covering nationwide regions [1] Group 1: Product Details - The four selected products include Glucosamine Hydrochloride Capsules, Torasemide Injection, Lidocaine Hydrochloride Injection, and L-Carnitine Injection, each targeting specific medical conditions such as osteoarthritis, heart failure, local anesthesia, and complications from chronic kidney disease [1] - Glucosamine Hydrochloride Capsules are indicated for the treatment and prevention of osteoarthritis, with selected specifications of 750mg in 120 capsules and 750mg in 60 capsules [1] - Torasemide Injection is aimed at patients with edema due to congestive heart failure and liver cirrhosis, with selected specifications of 2ml:10mg in 10 vials and 4ml:20mg in 5 vials [1] - Lidocaine Hydrochloride Injection serves as a local anesthetic and antiarrhythmic agent, with a selected specification of 5ml:0.1g in 5 vials [1] - L-Carnitine Injection is for patients with chronic kidney disease undergoing long-term dialysis, with selected specifications of 5ml:1g in 5 vials and 5ml:2g in 5 vials [1] Group 2: Revenue Contribution - Among the four products, Glucosamine Hydrochloride Capsules are the core product, contributing significantly to revenue, with projected sales of 334.89 million yuan in 2024, accounting for 46.88% of the company's total revenue for that year [2] - For the first three quarters of 2025, the revenue from Glucosamine Hydrochloride Capsules is expected to reach 345.37 million yuan, representing 57.85% of the company's revenue during that period [2] - The other three products have relatively smaller revenue contributions, with Torasemide Injection generating 6.55 million yuan in 2024 and 4.20 million yuan in the first three quarters of 2025, accounting for 0.92% and 0.70% of total revenue, respectively [2] - Lidocaine Hydrochloride Injection and L-Carnitine Injection have minimal revenue, with figures below 0.1% for the respective periods [2] Group 3: Procurement Process - The centralized procurement process involves a coalition of provinces and regions across the country, led by Jiangsu, Henan, and Guangdong provinces to conduct unified procurement [3] - During the procurement period, medical institutions will prioritize the use of the selected drugs and ensure the completion of the agreed procurement volume [3] - Any remaining procurement volume after calculating the volume-based ratio can be selected from other companies that meet the bidding criteria [3]

公开履历显示，王炳正生于1983年12月，历任兰石重装控股股东兰石集团下属子公司兰州兰石铸锻有限 责任公司技术研发部设计研发室主任、技术研发部副部长、总工程师，兰石集团铸锻分公司总工程师、 副经理、经理，兰石集团铸锻分公司党总支书记、总经理。目前，除任职兰石重装副总经理外，王炳正 还担任兰石重装子公司兰州兰石超合金新材料有限公司党委书记、董事。 中证报中证网讯(记者何昱璞)兰石重装（603169）2月11日晚间发布公告称，公司近日收到静宁县监察 委员会签发的《立案通知书》和《留置通知书》，公司副总经理王炳正因涉嫌违纪和职务违法犯罪问题 被立案调查和实施留置措施。 兰石重装表示，当前尚未知悉立案调查及留置的进展及结论，后续将持续关注上述事项进展，并及时履 行信息披露义务。目前，公司董事及其他高级管理人员均正常履职，公司生产经营情况正常，并未受到 影响。 上任不足5个月副总经理涉嫌违纪和职务犯罪 根据此前公告，王炳正于2025年9月15日被聘任为公司副总经理，至今任职时间不足5个月。 公开资料显示，兰石重装处于能源化工装备行业，现已形成能源化工装备制造、金属新材料、技术服 务、工程总包四大业务板块。 2025年1 ...

金泰源煤矿本次勘查范围占矿井总面积的11.84%，区内铝土矿累计查明资源量达512.95万吨，含控制资 源量194.31万吨、推断资源量318.64万吨；矿石开发效益显著，Al O 平均含量63.12%、A/S平均值 5.93。该矿伴生资源同样亮点突出，伴生金属镓保有推断资源量333.42吨、含量0.0065%，达到较好经 济效益品位要求，还探明山西式铁矿保有推断资源量63.76万吨，进一步丰富了公司矿产资源品类。 值得关注的是，两座矿井此次完成备案的资源量均仅来自部分勘查区域。业内人士推断，其全矿区的资 源总量与开发潜力或更为可观，将为公司长远发展持续注入资源动力。 永泰能源相关负责人表示，两座煤矿详查报告通过评审备案，为其后续申请办理采矿许可证奠定坚实基 础，也让公司积累了可复制、可推广的项目经验，将推动其余煤矿煤下铝资源的勘查与开发。据悉，公 司8座矿井预估铝土矿总资源量达1.16亿吨，随着各项目有序推进，企业煤下铝资源规模化、集约化发 展步伐将加快，核心竞争力资源集群也将逐步构建。 中证报中证网讯（记者 张鹏飞）2月11日晚间，永泰能源（600157）发布公告称，公司旗下金泰源煤矿 煤下铝矿产资源储量 ...

Core Viewpoint - The controlling shareholder of Pianzaihuang, Zhangzhou Jiulongjiang Group, has completed a share buyback, reflecting confidence in the company's long-term value and development potential [1][2]. Group 1: Shareholder Actions - Zhangzhou Jiulongjiang Group announced a plan to increase its stake in Pianzaihuang from February 1 to July 31, 2026, with a total investment of no less than 300 million yuan and no more than 500 million yuan [1]. - Following the buyback, the shareholding of Zhangzhou Jiulongjiang Group increased from 50.97% to 51.04%, with the number of shares rising from 30,752,264.43 shares to 30,795,774.43 shares [1]. Group 2: R&D and Innovation - Pianzaihuang has been actively investing in R&D, with a pipeline that includes 6 traditional Chinese medicine innovative drugs, 6 chemical drugs, 6 classic ancient formulas, and 1 innovative biological product [2]. - The company has 10 innovative drugs entering critical clinical stages, including PZH2108 for cancer pain, PZH2113 for anti-tumor treatment, and PZH2107 for fibromyalgia, all of which have completed the first subject enrollment in their respective clinical trials [2]. - The ongoing R&D efforts are expected to enhance the company's position in the traditional Chinese medicine sector and contribute to the innovative development of the industry [2].

Group 1 - The core viewpoint of the article is that Fulei New Materials (605488) has disclosed its fundraising situation, raising a total of 707 million yuan through a private placement of shares priced at 32.66 yuan per share [1] - The total number of shares issued is 21.6473 million, with a net fundraising amount of 692 million yuan after deducting related expenses [1] - The raised funds will be used for expanding production projects related to label printing materials, upgrading electronic-grade functional materials, enhancing the R&D center, and supplementing working capital, all aligned with the company's main business [1] Group 2 - A total of 16 investors participated in the issuance, including well-known institutions such as Huatai Asset Management, Caitong Fund Management, and Nord Fund Management, all subscribing to the shares in cash [1] - The total amount raised does not exceed the amount approved by the company's board and shareholders, and registered with the China Securities Regulatory Commission [1] - The shares subscribed by investors will be subject to a six-month transfer restriction from the end of the issuance, unless otherwise stipulated by laws and regulations [1]

Core Viewpoint - China State Construction Engineering Corporation (CSCEC) reported a steady growth in new contract signings for January 2026, indicating resilience in its business operations and a positive outlook for the construction industry [1][2]. Group 1: Contract Performance - In January 2026, CSCEC achieved a total new contract signing amount of 399.5 billion yuan, representing a year-on-year increase of 1.8% [1]. - The construction business segment saw new contract signings of 383.8 billion yuan, with a year-on-year growth of 1.6% [1]. - The housing construction segment specifically recorded new contract signings of 274.3 billion yuan, reflecting a significant year-on-year increase of 15.9% [1]. - Domestic new contract signings amounted to 361.7 billion yuan, showing a modest year-on-year growth of 0.3%, while overseas new contract signings reached 22.1 billion yuan, marking a robust year-on-year increase of 29.5% [1]. Group 2: Physical Indicators - The physical indicators for housing construction included a total construction area of 1.388 billion square meters, with new construction area of 16.71 million square meters and completed area of 15.57 million square meters [1]. Group 3: Real Estate Business - In January 2026, CSCEC's contract sales in the real estate sector totaled 15.7 billion yuan, which is a year-on-year increase of 6.9%, with a contract sales area of 520,000 square meters [1]. - The company reported a land reserve of 67.73 million square meters, indicating a sufficient supply of land for future projects [1]. Group 4: Major Projects - CSCEC has been steadily advancing major project constructions, with a total of 37.24 billion yuan in significant project amounts recently secured [1]. - This includes four housing construction projects, such as the Singapore Alexandra Hospital IP segment, totaling 18.37 billion yuan, and four infrastructure projects, including the reconstruction of the Fuyin Expressway in Xiangyang, amounting to 18.87 billion yuan [1]. Group 5: Future Outlook - Looking ahead to 2026, CSCEC aims to align closely with national policy directions, seizing industry development opportunities while accelerating its transformation towards high-end, intelligent, and green construction [2]. - The company is focused on enhancing both development quality and efficiency, with the goal of maintaining its leading position in the global industry and creating greater value for shareholders, clients, and society [2].